LEADING PRODUCT CANDIDATE
SymphonyTM
Bluejay Diagnostics is pleased to present Symphony, a near-patient biomarker detection platform. Symphony aims to help improve healthcare outcomes by providing quantitative clinical chemistry results vital for triage and acute care..
Symphony is an innovative implementation of the traditionally reliable ELISA methodology combined with modern advances in nanotechnology. The unique design features a combination of microfluidics and interrupted fluid dynamics to offer fast, simple, safe, and highly sensitive biomarker detection.
*Not FDA cleared. For research use only


WHO WE ARE
Bluejay Diagnostics is focused on improving patient outcomes through a more cost efficient, rapid, near patient product for triage, diagnosis, and monitoring of disease progression.

PRODUCTS IN DEVELOPMENT
Symphony is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. Symphony utilizes a ‘sample-to-result’ format, which means that once a specimen is taken from the patient, it is placed in the cartridge and then the cartridge is placed inside the analyzer where the test is run without further technician intervention or additional reagent. This reduces test complexity and eliminates the need for highly trained and expensive laboratory technicians to run the tests.
Our platform is designed to enable simple, rapid, and cost-effective analysis from a single clinical sample, which will allow LTACs, hospitals and clinics that traditionally could not afford more expensive or complex diagnostic testing platforms to modernize their laboratory testing and provide better patient testing at an affordable cost in time sensitive, life threatening situations.
LATEST NEWS
Highlights

Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass. , Nov. 13, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board.

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
ACTON, Mass. , June 28, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics , Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm.

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock.
OUR TEAM
Meet the Bluejays

Neil Dey

Jason Cook

Les DeLuca

Diane Palermo

Amit K. Roy

Lekha Papammagari

Tina McCarthy
OUR TEAM
Meet the Management Team

Neil Dey

Jason Cook

Les DeLuca

Diane Palermo

Amit K. Roy

Lekha Papammagari
